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The effects of infusing human alpha-caleltonin gene-related pep-
tide were studied in eight patients with congestive heart failure,
five normal rabbits and five rabbits with adrimnyein-induced car-
diomyopathy. In patients with heart failure, eatclonin gene-related
peptide ranged a dose-dependent increase in cardiac output and
decrease in pulnnmary,
and systemic vascular resistance and pdmo-
nary artery pressure . The systemic bland prison and right ahial
and pulmonary wedge prennares decreased oal5 at The highest
infesian rate (1d ngdrg per min), Heart rate remained unchanged .
Plasma epinephrine increased (p < 0.05), whereasaldosteeone, Atria][
natrluretic peptide and prolaemin euncentradons decreased Ip <
Calcitonin gene-related peptides are a group of recently discov-
ered regulatory neumpeptides with widespread distribution in
humans and animals . These peptides are leveled in the central
and peripheral nervous system (1-3), the heart and blood
vessels
(0,5)
. Rat and human alpha-calcaonin gene-related
peptides have been synthesized and the human peptide is found
circulating in blood at relatively high concentrations
(6)
. In the
heart and blood vessels, specific binding sites have been
identified (7-9) . Calcitonin gene-related peptide acts on these
receptors to exert powerful cardiovascular effects ., including
positive chronotropic and inotropic actions on the heart, by-
potension and vasodilation in humans and several animals
(9-15)
. These effects are independent
of beta-adrenergic and
histaminergic receptors or blockade of prostaglandin synthesis .
Calcironin gene-related peptide stimulates the inward calcium
current in the bullfrog heart, seemingly mediated by the stim-
ulation of adenyiate cyclase (16) .
In contrast to the vasodilation produced by acetylcholine
and sodium nitropmsside, which increase cyclic guane'ine
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0.05). Plasma nmepinephrine, resin activity, cerlfaai and growth
harness crnnatratiaas remained unchanged-
In truth groups of rabbils, the drug decreased blood pressure and
Increased cardiac output and heart rate. There was a significant
Increase in renal blood flaw (p < 0.05), The peptide did net Wkd the
contraction amplitude of human and rabbit
ventricular
nyacyles.
These findings suggest that eelellonin gene-related peptide Is a
vasaddator in The rabbit and bandana with little direct effect on
ventricular myocardium. This peptide may be awful in same
forms of heart failure .
U Am Call Cardfui 1991;17:205-l71
monophosphate in the smooth muscle, the effect of calcilo-
nin gene-related peptide is not accompanied by guanosine
monophusphate accumulation 1171 and the vasodilalion is
nonendothelium-dependent (18) . Intravenous capsaicin stim-
ulates the release of endogenous calcitonin gene-related
peptide, causing vasodilation, hypotensian and a depletion
of the peptide from nerve fibers in the myocardium and
around the coronary vessels (9,19) . These findings suggest
.hat endogenous calcitonin gene-related peptide may play a
role in modulating coronary and peripheral vascular tone .
Moreover, a combination of the reported positive isotropic
effect on the heart and arterial vasodilation may be beneficial
in the treatment of congestive heart failure.
In this study, we investigated the effects of infusing
human ulpho-ealcitnnin
gene-relatedpepilde on
1) hemody-
namics and plasma hormone concentrations in patients with
severe congestive heart failure; 2) hemadynamics and tissue
blood flow in normal and cardiomyopathic rabbits ; and
3) isolated myocytes from normal rabbits and patients un-
dergoing cardiac transplantation or valvular surgery .
Methods
Human Experiments
Study patients . The human studies were carried out in
eight patients admitted far the control of congestive heart
failure : six were male and two female, with an average age of
rags-1597 .0 Psi .vu
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37 years (range 17 to 50) . One had ischemic heart disease
; all
other patients had dilated cardiomyopathy. The diagnosis
was confirmed by cardiac catheterization and coronary
angiography
. All patients were short of breath (New York
Heart Association functional class III or 1V) . Edema was
present in three patients ; jugular venous pressure was raised
in all and the liver was enlarged in seven . All patients had
clinical cardiomegaly and a left ventricular third heart sound .
Four patients had evidence of mitral regurgitation . The
average cardiothoracic ratio was 62 .4 ± 2.6% on chest X-ray
study. All routine laboratory investigations, including
plasma electrolytes, creatinine and blood urea nitrogen,
were within the normal limits. Five patients were taking
digoxin (0 .25 mg/day), all were on an oral diuretic drug
(average furosemide dose 57 ± 8 mg/day) and three patients
were taking captopril (25 mg three times a day).
Hemodynamics . Hemodynamics were measured with a
Swan-Ganz catheter . Arterial pressure was measured using
intraarterial cannulation of the left brachial artery using
a 3F teflon catheter (Seldicath) . Pressures were measured
with Hewlett-Packard model 1290C transducers and a
Hewlett-Packard model 78354A monitor. Cardiac output
was determined by thermodilution (SPI445, Gould Idstru-
ments) . Hemodynarnic variables were derived using stan-
dard formulas .
Hormone assay . Hormone assays were carried out in a
30 ml blood sample drawn from a forearm vein. Plasma
norepinephrine and epinephrine were measured by high
performance liquid chromatography with electrochemical
detection . Plasma resin activity, atrial natriuretic peptide,
aldosterone, cartisol, prolactin and growth hormone were
measured by radioimmunoassay ( .0 .21) . Plasma concentra-
tions of calcitonin gene-eclated peptide were measured by
nonequilibrium radioimmunoassay employing a commercial
kit (ITS, Immunotechnolugy Service Production) . with a
standard curve range of 2.5 to 250 pLVml . Plasma samples
were assayed after a simple solid-phase extraction CS"-Pak
C 10 cartridges) . Analytical recovery of synthetic calcitonin
gene-related peptide (128 pg/mu added to plasma before
extraction was 60% to 70r/c (mean 677x ; n = 10). The mean
concentration of eir ulc :iob alcitunin gcuc-related pcpt: c
in human extracted plasma from 20 normal subjects was
11 .3 ± 4 .7 pg/ml (range 2 .5 to 19 .6) .
Protocol . The studies were performed in the postabsorp-
tive state during the afternoon, 3 h after a light lunch and
6 h after the last cardiac medication . Alter instrumentation,
patients were allowed to rest in bed for I h . After baseline
measurements, a blood sample was Men from a peripheral
vein for estimation of basal hormone levels. Infusion of
human alpha-calcitonin gene-related peptide (Celltech Ltd .)
was then started into a forearm vein using an infusion pump
(Harvard Apparatus. model 902), Incremental infusions of
calcitonin gene-related peptide at the dose of 0 .8 . 3 .2 and
16 ng/kg per min were made (2.16
x
10 - `, 8 .3 x 10 ° and
4.2 x 10 - '' mol/kg per min). The first two doses were
infused for 10 min each . Al the end of each 10 min infusion
2(r
period, all hemodynamic measurements were recorded . The
highest dose of calcitonin gene-related peptide !
16 nglkg per
min) was infused for 20 min
. At the end of this period .
hemodynamic measuremcnts were repeated and a second
blood sample for hormone assay was taken from a peripheral
vein of the contralateral arm to that being infused . The
infusion was then stopped . Heetodynamic measurements
were continued for I h .
The human studies were performed after obtaining writ-
ten informed consent from the patients . Ethical clearance
was obtained from the Hospital Ethics Committee. The
animal experiments were in conformity with the position of
the American Heart Association on Research Animal Use
and was cleared by the Hospital Ethics Comm)ttee .
Animal Experiments
Study animals. Experiments were carried out in two
groups of five New Zealand White rabbits, weighing 1 .9 to
3 .1 kg . The first group of five control rabbits received no
treatment . The second group of five animals received adri-
amycin into an car vein at a dose of 1 mglkg body weight,
twice weekly for 7 weeks. We i22' previously showed this
treatment to cause cardiomyopathy in rabbits. The adriamy-
cin-treated animals were allowed a 2 week injection-free
/'cried to recover from the hematologic and renal toxicity .
Polyethylene catheters were then implanted into the right
atrium, left ventricle and ascending aorta . A specially de-
signed thermistor catheter was inserted into the left femoral
artery and advanced into the descending aorta. This was
used for determining cardiac output by thermodilution (22) .
The surgical technique has been described in detail (22)
.
Protocol. Forty-eight hours after surgery, the rabbits
underwent hemodynamic study in the conscious unre-
strained state . Control measurements of heart rate, right
atrial pressure • mean aortic pressure, cardiac output and
regional blood flow were made . Human alpha-calcitonin
gene-related peptide was infused into the right atrium using
an infusion pump. The infusion was begun at I x 10
-II
mollkg per min. Heart rate, aortic pressure and cardiac
sere measured even 2 min. The infusion rate was
increased every 5 min unx cardiac output increased by
approximately 25% . The final dose was infused for 10 min
before hemodynamic measurements were again taken and a
second determination of regional blood flow made using
different radiolabeled :nicrospheres. The average final dose
for the control animals was 4 .06 x 10-10 mol/kg per min
compared with 5 .8 x 10- 'o mo!ikg per min for the adriamy-
cin-treated animals (p > 0.05) .
The animals were killed using an excess of intravenous
pentobarbilone . The heart, brain, kidney, spleen and small
samples of small gut, skin and soleus and quadriceps mus-
cles were removed. weighed and processed for radioactive
counting t calculate the tissue blood flow and vascular
resistance values (22). Gadolinium-153- and Scandium-46-
labeled nicrospheres (New England Nuclear Ltd .) were
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Table 1 . Hemodynamic Charges With Infusion of 0 .8. 3 .24 and 16 ng/kg per min of Calcitonin Gene-Related Peptide (CGRP) in Eight
Patients With Congestive Heart Failure
-p < 0.001.'p < 0,0i . /p < 0 .005 compared with basal values . aota are mean * S0,
used (unless stated otherwise) because of their relatively
long half-life, different energy spectrum and ease of sepora-
lion in a gamma counter.
Isolated Cardiac Myocytes
Protocol . The direct myocardial effects of calcitonin
gene-related peptide were determined in isolated rabbit and
human myocytes . Myocytes were isolated front three normal
rabbi) hearts by Langendorff perfusion with a low calcium
solution (9 samol/litcr), followed by a 2 min perfusion with
solution containing collagenase and hyaluronidase (23). Hu-
man
ventricular
myocardial cells were obtained from the
explained hearts from two patients with coronary artery
disease (left ventricle from a 48 year old man and right
ventricle from a 63 year old maul and from the left ventricle
of a 62 year old woman at the time of milra : valve replace-
ment . Pieces of ventricle (t00 mg to 3 g) were quickly
chopped into cubes of approximately I min' using an array
of razor blades
. The ventricles were incubated for a total of
12 min at 35'C in 25 to 50 ml of the low calcium medium
containing I to 2 µmolditer calcium . The medium was
changed three times during this period, and the tissue was
stirred by bubbling with 100% oxygen . The low calcium
medium was removed by straining with 330 µcool/liter cal-
cium added . followed by two 45 min periods with the
protease (pronase) and 30 9amol/liler calcium added, fol-
lowed by two 45 min periods with the protease omitted and
400 IU/ml of collagenase added . The medium was shaken
gently throughout the incubation and kept under an atmo-
sphere of 100% oxygen
.
At the end of each 45 min period, the solution containing
the dispersed cells was filtered through a 300 µm gauze and
centrifuged at 40
x
for I to 2 min . Isolated cells were
superfused with a modified Krebs-Ifensleit solution contain-
ing calcium (I mmol/)iter) equilibrated with 95% oxygen and
5% carbon dioxide at 32 ° 0 .5°C and electrically stimulated
(at 0.5 Hz, 5 ms, suprathreshold voltage), The contraction
amplitude of the myocytes was measured in a perspex
chamber, using a video camera edge detection system linked
±ACC Vat. 17 . No . I
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to an inverted microscope (23) . The spatial resolution of the
system was I in 256 and the time resolution 20 ms . Contrac .
lion was expressed as percent cell shortening .
In the rabbit myocytes, the effects of I x 10 - ° to I x 10
-7
moliliter of calcitonin gene-related peptide on the percent
cell shortening was investigated cumulatively . In four human
cells, the effect of I x 10 -7 molditer of calcitonin gene-
related peptide was measured, whereas in two other cells,
the effects of 10
-s
and 10 -° mopliter of calcitonin gene-
related peptide were investigated. Each concentration of
calcitonin gene-related peptide was in contact with the cells
for 5 min . At the end of the experiment, the effect of calcium
(8 mmol/liter) was also investigated .
Statistics. Data are expressed as mean t standnrd devi-
ation unless stated otherwise . The probability of the differ-
ence between paired and unpaired data was calculated by
Student's I test .
Results
Human Fxperimenrs
Hemodynamics (Table 1). The rest basal hemodynamic
data in the eight patients showed severe cardiac dysfunction
as judged by reduced cardiac output (1 .6 t 0-27 liters/min
per m 2 ) and increased pulmonary artery wedge pressure
(23 .5 ± 6.4 mm Hg) and pulmonary and systemic vascular
resistance (470 ± 194 and 2,374 ± 309 dynesis per con' .
respectively) . The lowest dose of calcitonin gene-related
peptide (0.8 ng/kg per min) caused a small (7 .9%) decrease in
systemic vascular resistance (p < 0 .005) and a similar
increase (7%) in cardiac output (p < 0 .05) (Fig. I and 2). The
heart rate did not change . Calcitonin gene-related peptide at
the dose of 3 .2 ng/kg per min caused a further reduction in
systemic vascular resistance (20%p, p < 0
.002) and increase
in cardiac output (24%, p < 0 .002) . At this dose, pulmonary
vascular resistance also decreased (71%, p < 0 .004) and
there was a slight decrease in the mean pulmonary arterial
pressure (5%, p < 0 .05) . Systemic blood pressure did not
change.
CGRP InPosion Inekg per mil
I h
aural 0.8 3 .24 16
`
Pos!Infuslon
Heart rate (bean%mint Im 6 ± 17.5 101.R
t
16 .5 103 .0 ± 17.3 105 .3 ± 170 163 .6 ± 104
Right a trial preswre (mean mm Hg) 9 .1 ' 5r2 9.3 ± 5 .2 8 .6±5.6 6 .8x4 .4' 7 .6±4.6
Pulmonary artery pre ssnre Imcan mm Hgl 38,4 ± 3 .9 '7.2 ± 9 .4 365
0
5.53 29 .4 ± 10.40 34,9 _ 12 .0
Pelmonarv artery wedge pressure (mean mm Hg) 23 .5 ± 6.4 22 .6 ± 6 .0 21 .7±4.9 13 .5e6.Ot 19 .8±6.41
Systemic arterial pressure (mean mm Hgl
83 .9 ± 13
.1 83 .5 ± 13
.8
83
.01 15
.3 66 .6! 12.41 78 .2±8
.9
Cardiac index duels/min per m'1 1,6 x D.27 1 .7
r
0 . 2 83 2 .0 ± 0.321 2 .74 ± 0.53' 2 .01 ± 0.551
Stroke volume codex 1 .1 be .,, per m''1 15 .9 ± 3 .6 17.3 ± 4 .3t 20 .2x4.50 26 .2±3T 19 .5±4.71
Pulmonary vascular resistance Icy- u-cm `I 470 ± 194 433 ± 227 372 :2241 284 ± 140' 364 ± 217
Systemic vascular re,ishmee (dynes s on `I 2 .374 ± 309 22.187 ± 2633 ;,907 ± 3300 1 .136 ± 192' 1 .831 ± 3731
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Figure 1. Hemodynamic data before, during
and after (Puss) calcitonin gene-related pep-
tide (CGRPI infusion in eight patients with
congestive heart failure .
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Figure2
. Htanodynami
.uatabefoze, during
and after (Post) calcitonin gene-related pep-
tide (cGRPI infusion in eihhl paticnls w/h oars
congestive heart failure
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At the oighest dose of calcitonin gene-related peptide
(16 nglkg per min), systemic and pulmonary vascular resis-
tance decreased further (52%, p < 0.001 and 40%. p < 0.001 .
respectively)_ Cardiac output increased by 67%- (p < 0-001) .
arterial pressure decreased by 21% (p < 0 .004) and pulmo-
nary arterial and pulmonary artery wedge pressures de-
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pre
After the infusion was discontinued, hemodynamics
Caeaae Index
txtrN/mN/m%
P • 0.aa,
. .anx
P .a-oas
Prdnlar,ary Artwr W
.dg
. Pnmon.
BASAL 06 3.24 16.0 10 30 60
.IVKVI.*. mined"
cow
Infusion Post
Pulmonary Artery PP .a1WA
00
Imm15)
ns
xo
p o.ros
'9°
r
immHg)
BASAL 00 2.241 ¢.O 0
30 0
ngnK9/min minut.s
CGRP mlu .tnn Post m6ml .n
2 1 2
ANANLI PT SL
CAti-ITONIN GI NE-RLLAIEn PItPI'I1ll, IN HEART FAILURE
Tehle 2 . Ptnsma Hormone Levels Rerore and During Infusion of 16 egukg per min of Caleaonta Gene-Related Peptide /CGRP1 in a
Pa I lCM, W It h Conpev i ve Heart Failure Compared With Valses in 16 I N,,-1 Control Subjects
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arri I mono
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slowly returned toward the basal values, However, even I h
after the infusion had been stopped, cardiac output was
signifcantly higher (p < 0 .05) and pulmonary wedge pres-
sure and systemic vascular resistance significantly (p < 0 .05)
lower than the basal values . There were no complications or
side effects during the infusion . In particular, none of the
patients complained of flushing of the face or headache and
no patient developed any
arrhythmia,
.
Plasma hormones (Table 2) . Plasma hormone levels be-
fore the start of the peptide infusion and at the end of 20 min
at 16 ne/kg per min are shown in Table 2. Basal plasma
norepinephrine levels were consistently raised . Although
there was considerable individual variation, the average was
nearly three times that of control subjects (p < 0 .05). In
contrast, epinephrine levels were within normal limits,
Plasma renin activity varied greatly, although the mean
value was seven times that of control subjects (p < 0 .01)
.
Aldosterone and cortisol levels also varied widely . Plasma
atrial notriureric peptide concentration was raised in every
patient (p < 0 .0011. Growth hormone level was raised in all
but one patient Ip C 0 .0051 . Serum pmlaetin levels were
within the normal range
. The average basal level of cakito-
nin gene-related peptide was increased in the patients (range
12.5 (if 82 .4 pglrnl, mean 36.82
.
27 .61. There were, how-
ever, two patients who had levels within the normal range,
the values in our normal control subjects being 11 .33 ±
4 .7 pgiml (range 2 .5 to 19.6) . Calcitonin gene-related pep-
tide levels increased to five
times the basal value (185 .9
127 .2 pgrml) after infusion at the highest dose-
Caleitonin gene-related peptide infusion had no effect on
plasma norepinephrine
. Plasma epinephrine increased signifi-
candy from 119 ± 17 to 323 a 137 pg/mt (p <(;Z1. There was
no consistent change in plasma renin activity. Plasma uldosle-
ronc decreased in all but one patient
; the mean level decreased
from 366
.
135 to 263 t 138
peril
(p < 0.021 . Atrial natriuretie
peptide decreased in every case ; the average value decreased
from 385 t 45 to 250 ± 35 pg
)ml (p < OM) . Plasma growth
hormone and cortisol did not change . The prolactin levels
IACC V01. 17 . Ke . I
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decreased in all patients; the average level decreased from 11 .6
t 2 .1 to 9 .59 a 2
.1 ng/ml (p < 0.02).
Animal Experiments
Hemodynamics and tissue blood flow (Tables 3 and 4)
.
Seven weeks of adriamycin treatment caused the develop-
ment of cardiomyopathy in all five rabbits as judged by a
significant reduction in cardiac output (p < 0 .05), increase in
the total peripheral resistance (p < 0.05) and a redistribution
of tissue bland flow (Table 3) .
Calcitunin gene-related peptide caused a 17% increase in
heart rate in the five control animals (p < 0 .05) (Table 3, Fig.
3) . Although heart rate increased by 10% in the adriamyein-
treated group it did not reach a level of significance . Mean
blood pressure was reduced by about 30% in both groups
(p < 0
.051 . There was a significant increase in cardiac output
(p < 9.05), the effect being +31.2% in the control as
compared with +24.5% in the adriamycin-treated animals .
Total peripheral resistance decreased significantly by about
the same amount in both groups . Stroke volume index
increased in both groups, but the difference reached a
significant level only in the control group.
Calcitonin gene-related peptide caused a marked increase
in renal blood flow in both groups, but the effect was more
striking in the adriamycin-treate4 group . Myocardial and
skin blood flow was increased t,y calcitonin gene-related
peptide, but
:he changes did not :each significance in either
of the groups . Cerebral blood flow remained unaltered and
there was no consistent change in splenic, small gut or
skeletal muscle blood flow . The effect on the calculated
tissue vascular resistance is shown in Table 4 . Regional
vascular resistance generally reflected changes in the tissue
blond flow
. However, cerebral and myocardial vascular
resistance in both groups and the skin resistance in the
control group decreased significantly (p < 0 .05) . but these
were not accompanied by significant changes in tissue blood
Normal
p vane
leomrol P Value
fennel
Sutiasa
Patients
'basalt
Is .
b. .4
Padents
During CUNT
'basal as .
MIT)
Nnmpisayhrota tpe all 275 s 39 760 2 251 'A.05 755 a 163 NS
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flow to those organs. In addition. renal vascular resistance
decreased significantly in the adriamycin-treated rabbits .
Isolated Cardiac Mvocytes
Contraetlon umplltrde. No increase in contraction ampli-
tude was seen in either the seven rabbit myocytes (three
rabbits) or
in the four human cells tested (Fig. 4)
.
The
concentration of ceicitonin gcne-related peptide was in-
creased to 10 - ' meltliter in all cells and to 10 - s moliliter in
two of the human myocytes. Every cell subsequently
tested
showed increased contraction amplitude in response to
raised extracellular calcium, indicating that it had the poten-
tial to contract more strongly . The contraction amplitude in
a maximally stimulating concentration of calcium (8 mmoll
Titer in rabbit, 6 to 15 mmolfliter in human) is shown in Fig-
ure 4.
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Table 3. Effect of Cal citonm liene-Related Peptide on the Fl emodynamics and'fissue Blood Flow in Five Control and Five Ad riamycin-
'I'reated Rabbits
Coptrul Adriamycin-Treated
'P < 0 OS, 3p < 0-01 compared wish pre-dog levels, rp < OM edoamccin-ireeted e,J eonud rabbds before drug troelmenl- Data are mean
-
SD.
Discussion
to this study, we report for the first time the effects of
infusinns of human calcitnnin gene-related peptide on the
hemedynamics and plasma hormone
concentrations in pa-
items with severe congestive bean failure . In Addition, we
studied the hemudynamia and regional blood flow in groups
of normal and adtiamycin-treated rabbits . To test whether
caldi onin gene-related peptide has any direct inotropic
effects on the heart . we examined its effects on isolated
cardiac myocytes .
Nronan Study
Vasodilalirg effects . In patients with congestive heart
failure. infusion of calcitonin gene-related peptide caused a
dose-dependent decrease in systemic and pulmonary vascu-
lar
resist once and an increase in cardiac
output. The consid-
Table 4 . Effect of Catcilnnin GencRelwod Peptide on Tissue Vascular Resistance (dynes-s-cm7kgl in Five Control and Five Adriamycin-
Trcalcd Rabbit,
Control
Adriamycin-Treated
'p 1'1113 . Ip 11101 cnmp,ned ma6 pre .dmg perch: fp 11105 udnamyoioLnxlod oral mnlml whorls before dme neulm0OL DAM are moan 2 to.
Pre .drug Poll-drug Pre-dmg Post-drug
Hemodynamks
Heat ot,Ibeatslmin) 273A x 297 32-1A o 201' 286 x 40 315 .0 0 21 .2
Mean systemic pressure Imm Hgl 90 .4 x
172
612_69- 96.2x15 .1 63 .4x!5 .9`
Roht aI i l pres14l .  Imo
HO 04
05 01100
0 .030 .8 In-1 .4
Cardiac output Imllmir per kgl 342 .2 0 96.0 049 x 137' 230,2 x 43
.21
286.6 x 5&7-
Stroke volume rode, Imbbea : per kg; 17.6 x 0 .38 : 38-0.15' 9 .8000.MS 0.91¢0.97
TotalpedpheratresutanceimmHg 0.277-0,12 0. :46 - 004' 023 0 0.0927 0.,, 034'
mVmia per la)
Tissue blood t : .. ImPmir per kg)
Mypcmdial 291 - 1 .94 721x 2 82 8.705 .7 10.103 .55
Ccrubml
1.1 w - 0.x4 1 .60'0.102 0.71x1116 0 .76 035
Rcaal 416 •_ -72 4 .85 0 1 S3- 2
.78 x List
4 .19 _ 1 .98•
Spleeic 6 .57 a 5.97 8 .82 _ 7 .,-5 2 .86 4 1 .44 2 .77 4 0.78
treat ?at 1 .7 a 1 .04 2 .1 x U.8 1 .15 20.5 6 1,41 2 0.73
Saleus 331 - 01) 0'6 n35 3187117 0.310.4
Qoednerpr 0074- 0.426 0.05,- -003 0 .076 x 0.63 0.58 x 0.054
Skin
0136 -- 0 04 0 27 = t 18 0.052 x 0.0271 0.072- x 0.0099
Pre drug
Post-drug Prc-dmg Post-dmg
Mvuc
:udlal 17 .46 x 7.M 0,10*- ,.51' 9,07 4.67x2.84
•
ccIohni 35 .0031 .7 67 .1 1 25 .9- 141 .6 '- 41 .1
92.3 x 14.51
Renal 25 .61 a 19.4 14 re a 6.17 43.3
0
22.85 18.8
x
10.13'
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23
.5 14.4
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9070,
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enable increase in cardiac output probably prevented a
decrease in blood pressure until the highest dose (16 nglkg
per min) was reached. The two lower doses of the peptide
did not cause any change in the left- or right-sided filling
pressures of the heart. At the highest dose, both the right
alrial and pulmonary arterial wedge pressure decreased .
This would suggest that the peptide behaves as an areriotar
dilator at low doses and a mixed vasodilator at high doses .
Recently, McEwan et al . (24) showed dilation of the forearm
resistance vessels in humans in response to direct brachial
artery infusion of calcitonin gene-related peptide
. blnximal
increase in forearm blood flow was obtained with infusion of
1
.2 to to n l0
- ' a
mallmid of calcitonin gene-related peptide
(4 to 40 nglmin) . They were unable to show any venoditation
Figure 4 . Percent shortening of human and rabbit cardiac myocytes
after treatment with various doses of calcitonin gene-related peptide
(CGRP) and calcium (Ca) . Max = maximal.
~anen .>s~x Human cardiac my"ytos
r	r _
5
a 7 am G
toy ICNWI fen
JACC vol . 17, No. I
lvauary 1471 :259-17
Figure 3. Percent change in hemody-
namic and tissue blood flow after infu-
sion of human alpha-calcitonin gene-
related peptide (CGRP) in five normal
rabbits (Solid lairs)
and five rabbits with
adriamycin-induced cardiomyopathy
(cross-bolded
iuest
. BP = Mood pres-
sure: SVR = systemic vascular resin-
tance ; VOL . = volume. "p < 0.05.
with infusion of up to 5 x 1f -j1 moVmin of the peptide
(20 nglmin) directly into the vein . This lack of effect on the
capacitance vessels, in contrast to a vesodilator effect seen
in our patients with the highest dose, may he due to the
higher rest venous tone in patients with congestive heart
failure or the higher final dose used in our patients .
Role of (aehycardia
. In normal human volunteers, intra-
venous calcitonin gene-related peptide bas been shown to
cause tachycardia (6,12,13,25), with either no change (25) or
a decrease in systemic blood pressure (6,12,13) . The lack of
reflex tachycardia in our patients even at the highest dose
thin caused a decrease in blood pressure is an interesting
observation. Such a response might occur when improve-
ment in hemodynamics is accompanied by a withdrawal of
sympathetic overactivity or it might reflect the barnreflex
+:D-urmalities seen in patients with congestive hear[ failure
(26). Conversely, the absence of a tachycardia response
might be the result of a specific effect of this peptide on the :
sinus node . Ono et al . (16) have shown that the chronotropic
effects of calcitonin gene-related peptide on the heart are
mediated through specific receptors that increase transmem-
brane calcium current (to -s to 10- moVliter), In the pres-
ence of the catecholamine isoproterenol, calcitonin gene-
related peptide has the opposite effect and blocks the
isoproterenol-stimulated calcium current . It is likely that in
patients with congestive heart failure, the combination of
high circulating levels of catecholamines and calcilonin
gene-related peptide block the development of lochycardia .
Peptide binding sites . Specific binding sites for calcitonin
gene-related peptide have been identified in the heart and
blood vessels (91
. In the at . the highest concentrations of
binding sites for calcitonin gene-related peptide are in the
right atrium, followed by the left atrium and right and left
ventricles . Positive isotropic effects of calcitonin gene-
related peptide seen in in vitro studies (9,27) are probably
MACC Vat 17, Nn . I
snorts 1991 :204-1 :
brought about by direct interaction of calcitonin gene-related
peptide with these receptors and are not influenced by
adrenergic, histaminergic and prostaglandin synthesis
blockade . In most species, the positive isotropic effects of
calcitonin gene-rotated peptide are seen in the atria and
not in the ventricle (10 .14,15) . In humans, the positive
inotropic effect of the peptide could be supressed by labe-
talol, an alpha- and beta-adrenoceptor blocker (12), which
suggests that the inotropic effect could have been caused
by reflex sympathetic stimulation . The effect of calcitonin
gene-related peptide on isolated myocytes has never
been reported . The lack of any il~ vitro inotopic effect
seen in our isolated ventricular myocytes suggests that
specific binding sites for this peptide may not he present in
the human and rabbit ventricles . The increase in cardiac
output seen in our patients and rabbits after calcitonin
gene-related peptide infusion is, therefore, most likely due to
altered hemadynamics and, in particular . the decrease in
afterload.
Hormone Studies
Plasma peptide concentration . The concentrations of
plasma hormones in our patients with congestive heart
failure are similar to those described previously (2g) . In
normal humans . relatively high concentrations of circulating
immunoreaclive calcitonin gene-related peptide have been
reported (25 to 941 -_ 14 .2 x 10 ° mollliter) (6,291 .
We measured calcitonin gene-related peptide using an ex-
traction procedure followed by radioimmunoassay and
obtained a mean value of 113 ' 4 .7 pglml . corresponding
m 3 n 10-11 r d uirer, much lower than the concentrations
described by others (6,29) . Although the concentration of
the peptide was increased in most patients with congestive
heart failure, there was considerable individual variation .
There was no correlation between the calcitonin gene-
related peptide concentration and baseline thermodynamics or
hormone levels. The increased level of the peptide in pa-
tients with congestive heart failure has not been reported
previously. The pathophysiologic significance is not dear,
but may reflect a role of this peplide in congestive heart
failure .
Plasma epinephrine and norepinephrine, Calcitonin gene-
related peptide infusion caused a significant increase in
plasma epinephrine and decrease in aldosterone, atrial
natriuretic peptide and prolaetin contentrations . An increase
in plasma .pinephrine and norepinephrine levels after
calcitonin geese-rotated peptide infusion has been described
by others {6.13) and may be related to the decrease in
systemic blood pressure and reflex sympathetic activation .
Norepinephrtnc did not increase in our patients, This disso-
ciation between epinephrine and norepinephrine levels
is unusual and may suggest a direct effect of the peptide
on the adrenal medulla. A reduction in atria[ natriuretic
peptide seen in every patient was probably due to a decrease
ANAND Er AL .
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in the filling pressures seen with calcilonin gene-related
peptide
.
Plasmareninandprolactin . Kurta el al . (305 administered
calcitonin gene-related peptide to normal human volunteers
in doses similar to those used by us and found an increase
in plasma renin activity . Plasma aldosterone did not change .
They examined the effect of calcitonin gene-related peptide
oil isolated juxtaglomerular cells and concluded that
the increase in resin secretion was the result of a direct
regulatory influence on the juxtaglomerular cells and not
necessarily due to a decrease in blood pressure. In our
patients, short-term infusion of calcitonin gene-relate . . pep-
tide did not change resin activity, although the plasma
aldosterone concentration decreased . The differences in
these findings cannot easily be explained . Calcitonin gene-
related peptide infusion caused a significant decrease in
prolaetin levels in our patients . Although the effect of this
peptide on pmlactin has not been reported before . calcita-
sin, which has structural homology with calcitonin gene .
related peptide, has been shown to exert an inhibitory effect
or prolacim secretion in patients with impaired renal func-
tion (31).
Animal Sardv
Adrinmycin eardiamyopathy . We have previously shown
(22) that the adriamycin treatment used in this study leads to
the development of cardiomyopathy, with reduced cardiac
output at rest, a flat Frank-Starling curve . increased total
body exchangeable sodium and a redistribution of regional
blood flow . This model of low output failure has been
successfully applied to study the effect of drugs in the
conscious animal at rest 1321 . The hemodynamic and re-
gional blood flow alterations observed in the adriamycin-
treated animals in this study resembled those report id by us
previously (22,32) and are similar to the changes seen in
patients with heart failure (33 .34) .
Hemody, amts effects . In the normal rabbits . calcitonin
gene-related peptide in doses that caused hypotension re-
sulted in an increase in cardiac output, heart rate and renal
blood flow . Qualitatively similar hemodynamic and tissue
blood flow changes were seen in the rabbits with heart
failure. In vitro studies have shown considerable variation in
the effects of calcitonin gene-related peptide in different
species . Thus. whereas it has positive chronulropic and
inotropic effects on isolated rat and guinea pig atria. it
does
not after the rate or force of contraction in the isolated rabbit
heap 110 .11). In our study, there was only a modest increase
in heart rate in the normal rabbits and no change in the
rabbits with heart failure despite a considerable decrease in
blood pressure,
Effects on renal and peripheral blood flow. Calcitonin
gene-related peptide increased renal blood flow and reduced
renal vascular resistance in both groups of animals . The
renal effects of this peptide, unlike those of utrtal natriurelic
peptide, have not been well studied- out an increase in renal
2 1 6
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olood flow has been shown to occur in the rat (351. The effect
of calcilonin gene-related peptide on other vascular beds was
not so impressive, This may be in part due To technical
factors . Skin and muscle blood flow is very small, so
that the
reliability of radioactivity counting is reduced . Thus, the
suhsmntial percent increase in skin blood flow after calcito-
nin gene-related peptide
did not reach ale vel of significance,
whereas the decrease in resistance was significant only in the
control animals. These limiting technical factor ; do not
apply to the brain
• where blood flow is considerable and
clearly did not significantly change during infusion of calci-
tonin gene-related peptide . However, the rcointenae :e of
blood flow in
the presence of a reduced perfusion rressure
implies a degree of vasodilation . Furthermore, there was a
significant decr:dse in resistance in the rabbits with cardio-
myopathy, which is cansistent with the presence of calcito-
nin gene-related peptide receptors in the cerebral arteries
(7,B).
Conclusion. The present study confirms that calcitonin
gene-related peptide exerts powerful pharmacologie effects
on the cardiovascular and endocrine systems, but the
physiologic significance of these effects remain to be
determined . The peptide may act directly through its
specific receptors and indirectly by influencing the release
and action of other cardiovascular transmitters, Exogenous
calcilonin gene-related peptide produced beneficial hemo-
dynamic effects during shorPlernt infusions in patients
with severe congestive heart failure and were attributable
to vasodilation and not a positive isotropic effect, As yet,
there is no report of
the development of tachyphylaxis
after prolonged infusion
. These cardiovascular actions of
calcitonin gene-related peptide along with its capacity to
increase renal blood flow suggest a useful role in clinical
cardiclogy .
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